Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "REBEL Cell Culture Media Analyzer"

Looking for quality documents?
publications icon
Accelerating analytical testing for GMP plasmid production
The challenges associated with gene therapy bioprocessing are numerous and burdensome, from scalability to Cost of Goods control, and from ensuring quality/consistency to accessing sufficient capacity and expertise. The consensus of opinion in the field is that a largely or fully automated process based upon a single, easy-to-use platform would be optimal, as would the adoption of single-use technology. The majority of challenges that arise with testing of gene therapy materials relate to time and accuracy. The CTech™ SoloVPE® and FlowVPX® slope spectroscopy technology is specifically designed to address these very issues Speaker: Paul Mania
publications icon
Advancing real-time monitoring of AAV vector processes
Q&A Podcast and write-up for Biomanufacturing experts which include Rachel Legmann, Director of Technology for Gene Therapy and Joe Ferraiolo, At-Line Director Bioanalytics Applications. Authors: Rachel Legmann, Joe Ferraiolo
publications icon
Lentiviral vector manufacturing process enchancement utilizing TFDF™ technology
By Thomas Williams, Oliver Goodyear, Lee Davies, Carol Knevelman, Michael Bransby, Kyriacos Mitrophanous and James Miskin Cell and Gene Therapy Insights
external link icon
Repligen Acquires Atoll GmbH
WALTHAM, Mass., April 04, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has acquired Atoll GmBH (“Atoll”) of Weingarten, Germany, an innovator and manufacturer of MediaScout® pre-packed chromatography columns used in process development and clinical manufacturing of biologic drugs. The acquisition of Atoll expands Repligen’s pre-packed column chromatography portfolio into high throughput process development screening, complementing the Company’s existing strength in clinical production-scale columns. The combined offering will provide bioprocessing customers with breadth and flexibility in choosing column size, chromatography media and packed bed formats.   Repligen purchased Atoll from UV-Cap GmbH & Co. KG on April 1, 2016 for a combination of $9.1 million in cash and 538,700 shares 1  of Repligen common stock, for total upfront consideration of approximately
news icon
Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
publications icon
Get in line: developing in-process analytical tools for gene therapy applications
Q&A Podcast and write-up for Biomanufacturing experts which include René Gantier, Director of Technology for Gene Therapy, Ramsey Shanbaky, Bioprocess Applications Manager, and Jay West, Principal Scientist at Bristol Myers Squibb. Authors: Ramsey, Rene, Jay West
publications icon
Evaluating DNA purity ratio determination with the CTech™ SoloVPE® System White Paper
Spectrophotometric analysis is one of the most common techniques used to quantitate nucleic acids in a solution. However, traditional fixed-pathlength spectrophotometers have limitations when determining the purity ratios of these molecules. In this study, the CTechTM SoloVPE system assessed theoretical DNA purity ratios by utilizing its variable pathlength method, known as Slope Spectroscopy. The method was evaluated by assessing the specificity, intermediate precision, repeatability, linearity, and accuracy of the theoretical purity ratios. The observed purity ratios from the SoloVPE system demonstrated great comparison to the theoretical purity ratios, verifying the SoloVPE system’s slope spectroscopy method to be preferable for this application. Authors: Nigel Herbert, Drusha Purohit, Hannah Mignault
news icon
Repligen Corporation & Univercells Technologies Partner to Enable Real-Time Monitoring of Viral Vector and Vaccine Biomanufacturing
news icon
Announcing the 2014 North America Technology Fast 500™ Rankings: Annual ranking of fastest growing North America companies
external link icon
Repligen to Present at the Stifel 2015 Healthcare Conference
WALTHAM, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced its upcoming presentation at the Stifel 2015 Healthcare Conference, being held next week at the Lotte New York Palace. Tony J. Hunt, Repligen President and Chief Executive Officer, will present a Company overview on Wednesday, November 18, at 8:00 a.m. EST. A live audio webcast of this discussion will be accessible through the Investor Events section of Company’s website. A replay of the webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A media
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support